Literature DB >> 32246448

Pharmaceutical Treatment for Heart Failure.

Xue Lin1, Ligang Fang2.   

Abstract

Heart failure (HF) is defined as a clinical syndrome resulting from structural or functional impairment of ventricular fillings or ejections of blood. Currently, HF is divided into three groups which include HF with reduced ejection fraction (HFrEF), HF with preserved ejection fraction (HFpEF) and HF with midrange EF (HFmrEF). Even though major advances have been made in treating HFrEF during the past decades, heart failure is a fatal disease. In this review, we briefly summarize the current advances in pharmaceutical managements for heart failure, which includes drugs used in acute heart failure as well as those that prevent heart failure progression, in each category major clinical trials are also described. In addition, information about some of potential new drugs are also mentioned. Traditional Chinese medicine also shows its potential in treating HF, and we are still lack of medicine to treat HFpEF.

Entities:  

Keywords:  HF with preserved ejection fraction; HF with reduced ejection fraction; Heart failure; Pharmaceutical management

Year:  2020        PMID: 32246448     DOI: 10.1007/978-981-15-2517-9_7

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  3 in total

1.  Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness.

Authors:  Annayya R Aroor; Srinivas Mummidi; Juan Carlos Lopez-Alvarenga; Nitin Das; Javad Habibi; Guanghong Jia; Guido Lastra; Bysani Chandrasekar; Vincent G DeMarco
Journal:  Cardiovasc Diabetol       Date:  2021-04-21       Impact factor: 9.951

2.  Editorial: Medicinal Plants in the Treatment of Myocardial Injury and Vascular Diseases.

Authors:  Mas Rizky Aa Syamsunarno; Zakiah Jubri; Yue Liu; Yusof Kamisah
Journal:  Front Pharmacol       Date:  2022-04-01       Impact factor: 5.810

3.  Are We Treating Heart Failure in Patients with Chronic Obstructive Pulmonary Disease Appropriately?

Authors:  William W Stringer
Journal:  Ann Am Thorac Soc       Date:  2020-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.